ciprofibrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| clofibrate derivatives, peroxisome proliferator activated receptor-alpha(PPAR-alpha) agonists | 658 | 52214-84-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Ciprofibrate is a new derivative of phenoxyisobutyric acid which has a marked hypolipidaemic action. It reduces both LDL and VLDL and hence the levels of triglyceride and cholesterol associated with these lipoprotein fractions. It also increases levels of HDL cholesterol.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 18, 2009 | UK Medicines and Healthcare Products Regulatory Agency (MHRA) | Winthrop Pharmaceuticals UK Limited |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Haematoma muscle | 37.00 | 34.40 | 6 | 256 | 1131 | 63487629 |
| Tonic clonic movements | 35.60 | 34.40 | 6 | 256 | 1429 | 63487331 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C10AB08 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Fibrates |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D002273 | Carcinogens |
| MeSH PA | D000960 | Hypolipidemic Agents |
| MeSH PA | D057847 | Lipid Regulating Agents |
| MeSH PA | D009676 | Noxae |
| MeSH PA | D020025 | Peroxisome Proliferators |
| CHEBI has role | CHEBI:35679 | antilipemic drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Mixed hyperlipidemia | indication | 267434003 | |
| Hypertriglyceridemia | indication | 302870006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.71 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor alpha | Nuclear hormone receptor | AGONIST | EC50 | 6.05 | CHEMBL | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| D03521 | KEGG_DRUG |
| 21149 | RXNORM |
| C0055775 | UMLSCUI |
| CHEBI:50867 | CHEBI |
| CHEMBL557555 | ChEMBL_ID |
| DB09064 | DRUGBANK_ID |
| C019304 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2763 | PUBCHEM_CID |
| 3438 | IUPHAR_LIGAND_ID |
| 4057 | INN_ID |
| F8252JGO9S | UNII |
| 004087 | NDDF |
| 320016006 | SNOMEDCT_US |
| 395957009 | SNOMEDCT_US |
Pharmaceutical products:
None